Ilsung Is Co., Ltd. (KRX:003120)

Market Cap	136.10B -14.0%
Revenue (ttm)	64.38B -7.6%
Net Income	1.20B -92.1%
EPS	173.16 -92.3%
Shares Out	6.97M
PE Ratio	112.79
Forward PE	n/a
Dividend	1,200.00 (6.05%)
Ex-Dividend Date	Dec 29, 2025

Volume	25,936
Open	19,380
Previous Close	19,530
Day's Range	19,310 - 20,050
52-Week Range	18,100 - 29,300
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1954
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003120

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 14, 2026

Data Sources Report a data error